Piper Jaffray analyst Matt O'Brien recommends investors take advantage of today's pullback and build positions in shares of Integra LifeSciences. The company reported Q2 results that missed expectations and lowered organic growth expectations for the remainder of the year due mainly to increased competition in the Dural Repair businesses, O'Brien tells investors in a post-earnings research note. The issues in Dural will be short-lived and the remaining key growth drivers are "very much on track or ahead of expectations, so the story definitely is not broke," the analyst adds. He raised his price target for Integra shares to $56 from $53 and keeps an Overweight rating on the name.